8-K: Avid Bioservices Issues $160 Million Convertible Senior Notes Due 2029

Avid Bioservices has completed a private offering of $160 million in convertible senior notes due 2029, with a 7% interest rate.

Summary

• Avid Bioservices has successfully issued $160 million in 7.00% convertible senior notes due in 2029.
• The notes are senior unsecured obligations and will mature on March 1, 2029, unless converted or repurchased earlier.
• Interest on the notes is payable semi-annually on March 1 and September 1, starting September 1, 2024.
• The notes are convertible at the holder's option under certain conditions before September 1, 2028, and at any time after that date until shortly before maturity.
• The initial conversion rate is 101.1250 shares of common stock per $1,000 principal amount of notes, equivalent to a conversion price of approximately $9.89 per share.
• This initial conversion price represents a premium of approximately 12.5% to the last reported sale price of the common stock on March 6, 2024.
• The conversion rate is subject to adjustments for certain events, but not for accrued and unpaid interest.
• The company may not redeem the notes before maturity.
• Holders can require the company to repurchase the notes at 100% of the principal amount plus accrued interest upon a fundamental change.
• The indenture includes standard covenants and events of default, including bankruptcy or insolvency events that would trigger automatic acceleration of the notes.
• The net proceeds from the offering were approximately $153.5 million, after deducting commissions and expenses.
• A portion of the proceeds will be used to repurchase and repay the company's 1.250% exchangeable senior notes due 2026.
• The company also amended its credit agreement with Bank of America, waiving defaults related to the 2026 notes and allowing the new note issuance.

Sentiment

Score: 7

Explanation: The document indicates a successful capital raise and proactive debt management, which is positive. However, the debt obligations and potential dilution from conversion temper the overall sentiment.

Positives

• The successful issuance of $160 million in convertible notes provides Avid Bioservices with significant capital.
• The company has secured a 7% interest rate on the notes, which is a reasonable cost of capital.
• The conversion premium of 12.5% provides a buffer for the company's stock price.
• The company has addressed the default on the 2026 notes and has a plan to repay them.
• The amendment to the credit agreement provides flexibility and avoids further defaults.

Negatives

• The notes are senior unsecured obligations, which means they are not backed by any specific assets.
• The conversion of the notes could dilute existing shareholders if the stock price increases.
• The company is obligated to repurchase the notes at 100% of the principal amount plus accrued interest upon a fundamental change, which could be costly.
• The company has incurred approximately $6.5 million in fees and expenses related to the offering.

Risks

• The notes are subject to standard risks associated with debt instruments, including interest rate risk and credit risk.
• The company's ability to repay the notes depends on its future financial performance.
• The conversion of the notes could dilute existing shareholders if the stock price increases.
• The company is obligated to repurchase the notes at 100% of the principal amount plus accrued interest upon a fundamental change, which could be costly.
• The company's stock price could be negatively impacted by the issuance of the notes.

Future Outlook

The company expects to use the net proceeds from the offering to repurchase and repay its 2026 notes and for general corporate purposes. The company may also enter into additional swap contracts.

Industry Context

The issuance of convertible notes is a common financing strategy for growth-oriented companies, particularly in the biotech and pharmaceutical sectors. This allows companies to raise capital while potentially limiting dilution if the stock price performs well. The amendment to the credit agreement also indicates a proactive approach to managing debt obligations.

Comparison to Industry Standards

• The 7% interest rate on the convertible notes is within the typical range for similar offerings by companies with a similar credit profile.
• The conversion premium of 12.5% is also within the typical range for convertible notes.
• The use of proceeds to repay existing debt is a common practice to improve the company's capital structure.
• The amendment to the credit agreement is a standard measure to ensure compliance with debt covenants.

Stakeholder Impact

• Shareholders may experience dilution if the notes are converted into common stock.
• Creditors are impacted by the new debt issuance and the repayment of the 2026 notes.
• Employees may be impacted by the company's financial performance and strategic decisions.
• Customers and suppliers may be indirectly impacted by the company's financial stability.

Next Steps

• The company will use a portion of the net proceeds from the offering to repurchase for cash a portion of the Companys 1.250% Exchangeable Senior Notes due 2026.
• The company will repay in full any remaining outstanding 2026 Notes by depositing the required payoff amount with the trustee under the indenture for the 2026 Notes.
• The company will monitor the stock price and conversion rate of the notes.
• The company will continue to comply with the terms of the indenture and the amended credit agreement.

Key Dates

Keywords

convertible notes, senior notes, debt financing, capital raise, convertible debt, repurchase, fundamental change, interest rate, conversion rate, dilution, credit agreement, amendment